AI & tech companies in Iceland

Iceland has roughly 380,000 people. Run the directory’s usual population-to-output arithmetic and you’d expect a handful of small companies and little else. The actual picture is the opposite: the most concentrated per-capita biotech and clean-compute story in Europe.

The flagship is Alvotech, the Reykjavik biosimilars company. FY2025 revenue was $593M, up 21% year-over-year, with adjusted EBITDA of $137M (+27%). Q4 2025 alone delivered $173M revenue. The 2026 guidance is $650–700M revenue and $180–220M adjusted EBITDA. The product portfolio is five approved on-market biosimilars (Humira, Stelara, Simponi, Eylea, Prolia/Xgeva) sold into 90 countries via partners, with a 30-asset development pipeline behind them. Alvotech is, in absolute revenue terms, larger than every other Nordic healthcare operator in the directory combined.

The 2025 risk story sits inside a single building. Following a July 2025 FDA inspection of the Reykjavik facility, Alvotech received Complete Response Letters on four BLAs simultaneously. The company plans to resubmit in Q2 2026. The uncomfortable part is that Alvotech is essentially a single-site manufacturer for a global biosimilars business, so one Form 483 from one facility can hold up multiple US approvals at once. That is exactly what happened. Whether the second manufacturing site comes online before the next inspection cycle is the underwriting question for the next two years.

Behind Alvotech sits Kerecis, the regenerative-medicine company that sold to Coloplast for $1.3B in 2023, the largest-ever Icelandic exit and one of the largest Nordic biotech exits of the cycle. Sidekick Health covers digital therapeutics. The bench is short, but per head of population it is dense.

The under-discussed advantage is energy. Iceland’s electricity is roughly 100% renewable (geothermal and hydro), and the country has surplus capacity beyond domestic demand. That makes Reykjavik one of the cheapest places in the EEA to run compute-intensive AI workloads, and hyperscaler tenant capacity is physically migrating to Icelandic data centres. None of that shows up in startup activity reports, but it is reshaping the country’s economy. No other Nordic capital can physically match Iceland on compute cost for a seriously GPU-bound AI company.

Innovation Centre Iceland is the public agency, and it operates at a scale matched to the population: you can get a senior decision-maker on the phone, which is not how Brussels works. Reykjavik University and the University of Iceland supply the technical pipeline, with biotech and computational sciences disproportionately represented. The labour pool is small enough that hiring 30 senior people fast is a genuine constraint. In exchange, the in-country network is tight enough that recruitment via warm intro works better than in any other Nordic capital.

The 2026 question is whether Iceland diversifies beyond its single flagship. The country has produced exactly one half-billion-dollar revenue operator and a small handful of consequential exits. Sweden spreads its output across hundreds of mid-scale companies; Iceland has nothing like that spread. Per-capita output and talent density, though, are the highest in the Nordic directory, and the geothermal-compute advantage stays with Iceland regardless of how the biotech bench evolves.

Iceland makes sense for specialised biotech with heavy compute requirements, AI products with serious energy budgets, and deeptech teams that want the cheapest clean energy available. It makes much less sense for anything that needs a 200-person engineering hire in year one; that is a Stockholm or Helsinki conversation. Cross-reference the directory’s Iceland listings for the full bench.